Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARANA neoadjuvant enzalutamide in localized prostate cancer
NL-OMON40287Phase 2Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in prostate cancer (PCa), sponsored by Netherlands Cancer Institute. Primary endpoints: Positive surgical margin rate and AR-chromatin binding patterns and tissue proliferation. Planned start Jun 2014; status: not yet recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON40287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40287.